1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
REGULATORY
PAFSC 2nd Committee Recommends Designation of Thalidomide, Imatinib Mesylate as Orphan Drugs
At a meeting on December 1, the Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) Second Committee on New Drugs recommended Fujimoto Pharmaceutical’s thalidomide, expected indication for erythema nodosum leprosum, and Novartis Pharma’s imatinib mesylate for patients with F1P1L1-PDGFRα-positive hypereosinophilic syndrome…
To read the full story
REGULATORY
- Japan to Launch Pilot Project for Adopting Fair Market Value in Clinical Trial Costs
February 28, 2025
- LDP Lawmakers Urge Generic Industry to Ramp Up Production
February 28, 2025
- J&J’s Lazcluze, Genmab’s Tivdak and More Drugs in Line for Japan Approval
February 28, 2025
- LDP, Komeito, Ishin Agree to Set Up Consultive Body for Social Security Reform
February 26, 2025
- Coordinate Patent Issues with Originators before Listing: MHLW to Generic Firms
February 26, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…